Pathway's power to boost, halt tumors may be promising cancer therapy target
(Penn State) A protein, called inositol-requiring enzyme 1 -- IRE1 -- may serve as a key driver in a series of molecular interactions that can both promote and, paradoxically, inhibit tumors in certain types of cancers, such as non-melanoma skin cancers, according to a team of molecular biologists. They add that this pathway's dual power may make it a tempting target for future research on the design of new types of anti-cancer therapeutics.
Platelet-activating factor-receptor (PAF-R) agonists are pleiotropic phospholipid mediators that influence multiple biological processes including the induction and resolution of inflammation as well as immunosuppression. Importantly, PAF-R agonists have been shown to modulate tumorigenesis and/or tumor growth in various cancer models by suppressing either cutaneous inflammation and/or anti-tumoral adaptive immunity. Notably, we have shown that systemic administration of a PAF-R agonist augments the growth of subcutaneously implanted murine melanoma tumors in a PAF-R-dependent manner.
This article is protected by copyright. All rights reserved. PMID: 30117145 [PubMed - as supplied by publisher]
Publication date: Available online 15 August 2018Source: Pharmacological ResearchAuthor(s): Robert RoskoskiAbstractThe Ras-Raf-MEK-ERK signal transduction cascade is arguably the most important oncogenic pathway in human cancers. Ras-GTP promotes the formation of active homodimers or heterodimers of A-Raf, B-Raf, and C-Raf by an intricate process. These enzymes are protein-serine/threonine kinases that catalyze the phosphorylation and activation of MEK1 and MEK2 which, in turn, catalyze the phosphorylation and activation of ERK1 and ERK2. The latter catalyze the regulatory phosphorylation of dozens of cytosolic and nuclear...
SKIN cancer symptoms are most commonly associated with moles on the skin. But this is only a sign of melanoma - non-melanoma skin cancer has a very different appearance. Are you at risk of either type?
CONCLUSION: The treatment of skin diseases based on topical delivery of siRNA, which act by inhibiting the expression of target transcripts, offers many potential therapeutic advantages for suppressing genes into the skin. PMID: 30084329 [PubMed - as supplied by publisher]
S, Suárez Conde I, Pereiro-Ferreirós M Abstract Actinic cheilitis is thought to be a premalignant lesion or a superficial squamous cell carcinoma. The prevalence of actinic cheilitis in Europe is unknown. The aim of this study was to determine the prevalence of actinic cheilitis in the Galicia region (north-west Spain). Secondary objectives were the description of risk factors of actinic cheilitis. A cross-sectional multicentre study in patients ≥ 45 years of age was performed in 8 dermatology departments in Galicia region during a 1-year period. The prevalence of actinic cheilitis was 31....
CONCLUSIONS: Adherence to quality of cancer care criteria at the different hospitals evaluated varied. Our findings could be useful for identifying areas for improvement at different hospitals. Future studies should focus on measuring both process and outcome indicators. PMID: 30093072 [PubMed - as supplied by publisher]
Skin cancer is the most common malignancy in the white population worldwide. It is divided into melanoma and nonmelanoma skin cancer (NMSC). Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common subtypes of NMSC and it is estimated that 2-3 million new cases occur globally each year. Malignant melanoma is the least common skin cancer; however, it is the most fatal one its incidence is alarmingly increasing. According to worldwide trends, skin cancer is the most prevalent malignancy in Colombia, by 2010 reached up to 20.2% of all cancer cases attended.
Background and objectives: The incidence of cutaneous malignancy in the United States continues to rise. Mohs micrographic surgery is increasingly utilized to treat both nonmelanoma skin cancer (NSMC) and melanoma. This tissue-sparing method produces the highest cure rates while leading to an esthetic result. However, due to the need for intraoperative pathologic assessment, these procedures can be time-consuming and may average several hours. New technology aimed at more quickly assessing specimen margins for malignant cells has the potential to cut down on operative times and improve efficiency.
Background: Previous retrospective studies have reported increased frequency of both malignant melanoma (MM, using population-based SEER data) and nonmelanoma skin cancer (NMSC) on the left side of the body. Population-based studies for basal and squamous cell carcinoma (BCC and SCC) have been very difficult as a database similar to SEER does not exist for NMSC, resulting in inferences from smaller retrospective cohorts to assess laterality. As Utah has one of the highest incidences of both MM and NMSC, we explored this question for both skin cancer types using a large database of all biopsies read by the University of Uta...